Crohn disease activity

Adults - Take 9 mg once daily in the morning for up to 8 weeks. Swallow capsules whole do not chew or break. For recurring episodes of active Crohn disease, a repeat 8-week course of budesonide can be given. Following an 8-week course of treatment for active disease and once the patient s symptoms are controlled (Crohn Disease Activity Index less than 150), budesonide 6 mg is recommended once daily for maintenance of clinical remission for up to 3 months. If symptom control is still maintained at 3 months, an attempt to taper to complete cessation is recommended. Continued treatment with budesonide 6 mg for more than 3 months has not been shown to provide substantial clinical benefit. 

Yekeler E, Danalioglu A, Movasseghi B et al (2005) Crohn disease activity evaluated by Doppler ultrasonography of the superior mesenteric artery and the affected small-bowel segments. J Ultrasound Med 24 59-65... 

In an observational study, 95 patients with Crohn disease activity index <150 were randomly assigned to 6-mercaptopurine (0.5-1.5mg/kg/day, n=30), Elental as an elemental diet (>900kcal/day,... 

Finally, Shafran et al. [52] presented recently an open-label study on the efficacy and safety of rifaximin 600 mg/ day for 16 weeks in the treatment of mildly to moderately active CD. At the end of the study, 59% of patients were in remission (as defined by a Crohn s Disease Activity Index, CDAI, <150) with a significant reduction of the... 

Neovascularization in artherosclerotic lesions may be regulated by VEGF, as this factor is over-expressed by different cells in the plaque tissue [40-42]. The increased serum levels of VEGF that correlate with disease activity in patients with Crohn s disease and ulcerative colitis, indicate a role for this cytokine in promoting inflammation. Most likely, increased vascn-lar permeability and/or wound healing via its pro-angiogenic activity are the basis for this effect [43]. 

Patients with mild to moderately active Crohn disease involving the ileum or ascending colon have been switched from oral prednisolone to budesonide with no reported episodes of adrenal insufficiency. Because prednisolone should not be stopped abruptly, tapering should begin concomitantly with initiating budesonide treatment. 

Crohn disease, moderate to severe For reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn disease who have had an inadequate response to conventional therapy. 

Elevated concentrations of TNF have been found in the joints of RA patients and the stools of Crohn disease patients and correlate with elevated disease activity. In Crohn disease, infliximab reduces infiltration of inflammatory cells and TNF production in inflamed areas of the intestine and reduces the proportion of mononuclear cells from the lamina propria able to express TNF and interferon. In RA, treatment with infliximab reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion and vascular cell adhesion molecule-1, chemoattraction, and tissue degradation. After treatment with infliximab, patients with Crohn disease or RA have decreased levels of serum IL-6 and C-reactive protein compared with baseline. 

Kader, H.A., et al. (2005) Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-betal, and IL-12p40 levels in Crohn s disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 100, 414-23. 

E. Therapeutic response The safety and efficacy of a single intravenous dose of Remicade were assessed in a randomized, double-blind, placebo-controlled study of patients with moderate to severe active Crohn s disease who had failed standard therapy. The primary end point was the proportion of patients who experienced a clinical response, defined as a minimum decrease in the Crohn s Disease Activity Index from baseline at the 4-week evaluation and without an increase in Crohn s... 

In a randomized, multicenter study in 94 patients, mesalazine 4 g/day for 12 weeks in a microgranular formulation was as effective as a standard dose of a glucocorticoid (6-methylpredisolone 40 mg/day) in mild to moderate Crohn s ileitis (Crohn s Disease Activity Index 180-350) (9). The group treated with methylpredisolone had a higher number of adverse events than those given mesalazine. The only adverse effect related to mesalazine was acute pancreatitis, which resolved on withdrawal. 

Proximal renal tubnlar proteinuria is a possible complication in patients treated with high doses of mesalazine, and it is clearly important to monitor renal function in these patients (SEDA-22, 394) (75). Two studies in 21 (76) and 95 (77) patients with ulcerative colitis and Crohn s disease have shown that proteinuria of tubular marker proteins is common and is related to disease activity rather than to treatment with mesalazine. Thus, tubular proteins are not useful predictors of an adverse renal response to the drug. Nephrotic syndrome with minimal change nephropathy has been described with sulfasalazine and mesalazine (SEDA-16, 427). 

Prolonged-release mesalazine also reduced disease activity in patients with mild to moderately active Crohn s disease. In Crohn s disease, mesalazine was more effective in preventing relapse in patients with isolated small bowel disease than in those with colonic involvement. Prolonged-release mesalazine appears to be as well tolerated as placebo, and the incidence of adverse effects does not appear to be dose related. Nausea/vomit-ing, diarrhea, abdominal pain, and dyspepsia are the most commonly reported. Reports of nephrotoxicity with this formulation are rare. 

Reichardt P, Dahnert I, Tiller G, Hausler HJ. Possible activation of an intramyocardial inflammatory process Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease. Eur J Pediatr 2002 161(5) 281-3. 

Mycophenolate has also been studied in various chronic inflammatory disorders, such as rheumatoid arthritis, pemphigus vulgaris, and psoriasis. In 70 patients with chronic active Crohn s disease, mycophenolate plus glucocorticoids produced benefit on disease activity comparable to azathioprine plus glucocorticoids (7). Two of the 35 patients randomized to mycophenolate had significant adverse effects that required drug withdrawal, namely rashes and vomiting. 

Best WR, Becktel JM, Singleton JW. Development of a Crohn s disease activity index. Gastroenterology 1976 70 439M4. 

The severity of ulcerative colitis may be assessed by factors such as stool frequency, presence of blood in stool, fever, pulse, hemoglobin, erythrocyte sedimentation rate, C-reactive protein, abdominal tenderness, and radiologic or endoscopic findings. The severity of Crohn s disease can be assessed by the Crohn s disease activity index, which includes stool frequency, presence of blood in stool, endoscopic appearance, and physician s global assessment. 

Tumor necrosis factor-a (TNF-a) is a pivotal proinflammatory cytokine in Crohn s disease. TNF-a can recruit inflammatory cells to inflamed tissues, activate coagulation, and promote the formation of granulomas. Production of TNF-a is increased in the mucosa and intestinal lumen of patients with Crohn s disease. Eicosanoids such as leukotriene B4 are increased in rectal dialysates and tissues of IBD patients and are related to disease activity. Leukotriene B4 enhances neutrophil adherence to vascular endothelium and acts as a... 

T. suis Live ova were used iu a humau trial agaiust Crohu s disease. After 24 weeks of treatmeut Crohu s Disease Activity ludex (CDAI) of eurolled patieuts showed a teudeucy towards a decrease to a better proguosis. Without adverse events, this new therapy may offer a unique, safe, aud efficacious alternative for Crohn s disease management (Summers et al. 2005). 

Elevated plasma levels of IL-1 have been detected in a wide range of different conditions that are characterized by inflammation such as rheumatoid arthritis (RA), acute arthritides (D13, E2, M5), Crohns disease (SIO), periodontitis (C16), sunburn (G20), bums (K34), endometriosis (F3), psoriasis (C5), gram-positive meningitis (Sll), and extended exercise in healthy volunteers (C9). In RA there is some correlation with disease activity (E2). In synovial fluid, biologically active... 

There is an epidemic of immune-mediated disease in highly-developed industrialized countries. Such diseases, like inflammatory bowel disease, multiple sclerosis and asthma increase in prevalence as populations adopt modem hygienic practices. These practices prevent exposure to parasitic worms (helminths). Epidemiologic studies surest that people who carry helminths have less immune-mediated disease. Mice colonized with helminths are protected from disease in models of cohtis, encephalitis. Type 1 diabetes and asthma. Clinical trials show that exposure to helminths reduce disease activity in patients with ulcerative colitis or Crohn s disease. This chapter reviews some of the work showing that colonization with helminths alters immune responses, against dysregulated inflammation. These helminth-host immune interactions have potentially important implications for the treatment of immune-mediated diseases. 

The clinical significance of the degree of bowel wall thickening in known CD patients is controversial. Several studies attempted to establish a relationship between maximum bowel wall thickness and clinical (Crohn s disease activity index, CDAI) and biochemical (erythrocyte sedimentation rate, C reactive protein) parameters of CD activity. However, almost all the results of these studies produced weak corre-... 

---